Atlas Trials

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT02874404 · COMPLETED

Trial details

NCT number
NCT02874404
Sponsor
University of Nebraska
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2016-10-07
Primary completion
2019-07-01
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.